FDA Approves RNAi Therapeutic Vutrisiran for hATTR Amyloidosis
Vutrisiran is the first and only FDA-approved treatment that’s demonstrated reversal in neuropathy impairment with subcutaneous administration once every 3 months.
Sleeping Through Infectious Disease and the COVID-19 Vaccine
Dr. Aric Prather discusses the pandemic, his research, and his presentation from SLEEP 2022 "Sleep in the Time of COVID: An Update on How Sleep Affects the Immune System".
Aric Prather, PhD: Blue Light Filters aren't the Answer to Sleep Issues
While there's evidence that blue light exposure can impact an individual's circadian system, Dr. Aric Prather explains that technology is only one factor of the complex issue.
Amy Licis, MD: Biological Markers of Sleep Disruption in Children with ADHD or Autism
Dr. Amy Licis details recent observations regarding potential underlying neurobiological reasons for sleep disturbance in pediatric patients with ADHD or autism.
The Role of Pain in Relation to Fibromyalgia and Insomnia
Data indicate that higher levels of perceived pain related disability and greater difficulty falling asleep was associated with increased anxiety levels in adults with fibromyalgia and insomnia.
Improving Sleep Behavior May Reduce Alcohol Use in Young Adults
While young adults may be resistant to drinking interventions, improving sleep behavior can indirectly reduce hazardous drinking.
Aric Prather, PhD: Sleep in the Ongoing and Protracted Impact of COVID-19
There are still many aspects of sleep health that need to be understood, especially in relation to the COVID-19 pandemic.
Amy Licis, MD: How Sleep Issues Impact Children with Autism or ADHD
Sleep issues are prevalent among children with autism or ADHD and both these common disorders are increasing. Any provider working with children is most likely going to encounter patients struggling with sleep.
Study Finds Bidirectionality Between Stress and Sleep Disturbance in Perinatal Women
The study from SLEEP 2022 is the first to explore directionality of sleep-stress relationships in a sample of perinatal women.
SLEEP 2022 Data Show Reduced Slow Wave Activity in Depressed Adolescents
Today in a late-breaking abstract from SLEEP 2022, data showed the reduction of slow wave activity in unmedicated adolescents with depression.
Aric Prather, PhD: Sleep and COVID-19 Vaccination in Naive Population
Dr. Aric Prather and his team at UCSF are running a large study that began in March 2021 which follows healthy individuals through the COVID-19 vaccination and booster process.
Assessing Sleep in Patients with Rheumatoid Arthritis Using Actigraphy
The study objective was to determine if actigraphy could serve as a complementary clinical tool for sleep evaluation in patients with rheumatoid arthritis.
Objective Measures Show Youth with OCD Do Not Experience Increased Sleep Disturbance
The findings presented at SLEEP 2022 differ from previous studies that evaluated the objective-subjective sleep patterns of this population.
Aric Prather, PhD: Sleep and Susceptibility to Infectious Disease, COVID-19
Sleep expert Aric Prather, PhD, presented a discussion at SLEEP 2022 that focused on how the immune system and sleep are related to the "ongoing and protracted" impact of the COVID-19 pandemic.
The Rare Disease Report Podcast: Myelodysplastic Syndromes & Acute Myeloid Leukemia
Expert Dr. Mikkael Sekeres treats patients with bone marrow diseases and in this episode he talks about treatment methods, clinical trial obstacles and the importance of reliable sources when it comes to rare conditions like MDS and AML.
Efanesoctocog Alfa Receives FDA Breakthrough Therapy Designation for Hemophilia A
Efanescotocog alfa is the first factor VIII therapy to be granted Breakthrough Therapy designation by the FDA.
Improve Shared Decision Making Between Providers and Patients with Rheumatic Disease
Research presented at EULAR aims to enhance communication with a conversation aid so patients can address challenges they encounter as a result of rheumatic and musculoskeletal disease with a rheumatologist.
Decreased Access to Buprenorphine Significantly Affects Minorities with OUD
Since the delivery of these medications were disrupted during the pandemic, members of racial and ethnic minority groups experienced an increased risk of opioid overdose, compared with White individuals.
Gerald Smetana, MD: What PCPs Need to Know About Monoclonal Antibodies and Paxlovid
Primary care provider Dr. Gerald Smetana shares key information and resources to give PCPs all they need know about prescribing outpatient therapies for COVID-19.
Timothy Fong, MD: Cannabis Comes with Concerns and Therapeutic Potential
The public perception of marijuana has shifted significantly, and Dr. Timothy Fong addresses how to keep up with progressive research and what risk factors still need to be better understood.
Marc Rothenberg, MD, PhD: EoE Receives First FDA Approval with Dupilumab
EoE expert Dr. Marc Rothenberg says it's a relief to know that the FDA has finally approved a drug for EoE.
Bimekizumab Offers Improvements Across Full Spectrum of Axial Spondyloarthritis in Phase 3 Trials
New Promising Phase 3 Bimekizumab Data Among Patients with Psoriatic Arthritis
Data from 2 studies evaluating adults with active psoriatic arthritis were announced today in preparation for EULAR 2022. The different population groups who received treatment were biologic-naive patients and TNF-inadequate responders.
Wonder Drake, MD: Sarcoidosis is a Disease of Exclusion
Sarcoidosis expert Dr. Wonder Drake got into the field after diagnosing a patient with the disease early in her career. In this interview she explains the best way to approach a suspected case of sarcoidosis.
Carolyn Rowley, PhD: Patients with Sickle Cell Disease are Born into Pain
Dr. Carolyn Rowley talks about the Cayenne Wellness Center's mental health initiative for individuals with sickle cell disease and shares the story of one of her first patients.
Wonder Drake, MD: Understanding the Progression Patterns of Sarcoidosis
In this interview, Dr. Wonder Drake shares physician resources and explains the unique presentation of sarcoidosis and how it varies by region.
Study Provides Novel Insight on OUD Diagnosis Factors in Opioid-Naive Patients
Presence of chronic liver disease, prior use of gabapentin and being discharged to a long-term hospital or rehabilitation center are among some of the factors associated with a new opioid use disorder diagnosis.
Regina Hartfield: SCDAA is Launching a SCD Clinical Trial Finder Mobile App
Sickle cell warriors are empowered to be part of the research and to be part of the solution, Regina Hartfield says.
Phase 3 Data Show Isatuximab Offers Progression Free Survival for Multiple Myeloma
Isatuximab in combination with carfilzomib and dexamethasone (Kd) demonstrate the longest median progression free survival (mPFS) on a proteasome inhibitor backbone in multiple myeloma patients who relapsed after a prior therapy, including lenalidomide.
New Study Supports the Reliability SCD Patient-Reports of VOC-Related Pain Crises
Investigators who say that assessing vaso-occlusive crises solely through medical utilization doesn’t provide a full picture of the SCD experience because many VOCs are managed from home, are now backed by research.
2 Clarke Drive Cranbury, NJ 08512